Multihance

Active Ingredient:: Gadobenate Dimeglumine
Origin:: EU

Multihance (Gadobenate Dimeglumine)

Q: What is Multihance used for?

Multihance is a gadolinium‑based contrast agent used during magnetic resonance imaging to improve the visibility of internal structures. It is indicated for liver, central nervous system, cardiovascular and whole‑body MRI examinations, helping radiologists detect lesions, assess vascular anatomy and evaluate disease extent.

Q: How does gadobenate dimeglumine work?

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons after intravenous injection. This creates a brighter signal on T1‑weighted MRI images, enhancing the contrast between blood vessels, tissues and pathological lesions, which facilitates more accurate diagnosis.

Q: What is the usual dose of Multihance?

The dose of Multihance is determined by the prescribing physician based on the patient’s body weight, the specific MRI protocol and the anatomical region being examined. Typical dosing follows the product label, and the exact volume to be administered is set by the radiologist or ordering clinician.

Q: Is Multihance safe in pregnancy or breastfeeding?

Multihance is classified as Pregnancy Category C, meaning it should only be used when the potential diagnostic benefit justifies any possible risk to the fetus. Limited data are available for breastfeeding; therefore, the decision to continue nursing should be made in consultation with the treating physician.

Q: How do I order Multihance from GNH India?

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and assists with import documentation.

Q: How does Multihance compare with other gadolinium contrast agents?

Multihance (gadobenate dimeglumine) is a linear gadolinium chelate that provides high relaxivity, offering strong vascular and tissue enhancement. Compared with macrocyclic agents such as gadobutrol, Multihance may deliver slightly higher signal intensity in certain liver and cardiac studies, but macrocyclic agents are generally considered to have a lower risk of nephrogenic systemic fibrosis in patients with severe renal impairment.

Q: How should Multihance be stored and handled?

Multihance should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vial should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations for injectable pharmaceuticals.

Q: How is Multihance given/administered?

Multihance is administered as an intravenous injection, typically as a rapid bolus or a power‑injector delivery, depending on the imaging protocol. The exact injection rate and volume are defined by the radiology department and the prescribing physician to achieve optimal contrast enhancement for the targeted MRI study.

Q: What are the most serious risks associated with Multihance?

The most serious risks include nephrogenic systemic fibrosis in patients with severe renal dysfunction and severe allergic reactions such as anaphylaxis. Cardiovascular collapse and rare severe skin reactions (e.g., Stevens‑Johnson syndrome) have also been reported. Prompt recognition and management of these events are essential.

Q: Who should not use Multihance?

Multihance should be avoided in patients with known severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis, and in individuals with a documented hypersensitivity to gadobenate dimeglumine or any component of the formulation. Caution is also advised for pregnant women and those with a history of severe allergic reactions.

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a solution for injection for intravenous use. It enhances magnetic resonance imaging in adult patients requiring detailed visualization of the liver, central nervous system, cardiovascular system, or whole‑body assessments.

GNH India supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product complies with EU regulatory standards and is distributed under strict quality‑assured conditions. It is available for bulk procurement and supports imaging departments in delivering accurate diagnostic results.

Manufacturer / TM Owner

Bracco Imaging Deutschland Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Multihance (gadobenate dimeglumine) is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging across several organ systems.
Liver MRI: provides high‑resolution images of hepatic vasculature and lesions, aiding detection and characterization.
Central nervous system MRI: enhances visualization of brain and spinal cord structures, facilitating diagnosis of tumors, vascular malformations, and inflammatory disease.
Cardiovascular MRI: improves delineation of cardiac chambers, vessels, and myocardial perfusion for functional and anatomical assessment.
Whole‑body MRI: offers comprehensive contrast enhancement for systemic disease staging and metastasis evaluation.

How It Works

Gadobenate dimeglumine is a paramagnetic gadolinium chelate that distributes in the extracellular fluid after intravenous injection. Its gadolinium ion shortens the T1 relaxation time of nearby water protons, producing a higher signal intensity on T1‑weighted MRI sequences. The resulting contrast enhancement highlights vascular structures and tissue perfusion, allowing detailed anatomical and functional assessment. The agent is rapidly cleared by the kidneys, providing a transient but strong enhancement suitable for timed imaging protocols.

Side Effects

Adverse reactions to Multihance are generally infrequent but can range from mild to severe.

Common Side Effects

Nausea: mild nausea or vomiting shortly after injection.
Headache: transient headache during or after the procedure.
Injection site discomfort: pain or warmth at the site of administration.
Warm sensation: brief feeling of heat throughout the body.

Serious or Rare Side Effects

Nephrogenic systemic fibrosis: a rare fibrotic disorder in patients with severe renal impairment.
Severe allergic reaction: anaphylaxis or bronchospasm requiring emergency treatment.
Cardiovascular collapse: hypotension or cardiac arrest in susceptible individuals.
Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before using Multihance, clinicians should observe several precautionary measures to minimise risk.

Renal function assessment: evaluate glomerular filtration rate to identify patients at risk of nephrogenic systemic fibrosis.
Pregnancy considerations: use only when benefits outweigh potential fetal risks, as the agent is category C.
Allergy screening: inquire about prior reactions to gadolinium‑based agents or iodinated contrast.
Concomitant nephrotoxic drugs: monitor renal status when patients receive agents such as aminoglycosides or NSAIDs.
Dosage guidance: follow the prescriber’s recommended volume based on body weight and imaging protocol.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Multihance may interact with certain conditions or medications, requiring careful assessment.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): markedly increased risk of nephrogenic systemic fibrosis; avoid use.
Cumulative gadolinium exposure: avoid sequential use of multiple linear gadolinium agents within a short interval.

Moderate Interactions (Monitor Closely)

Loop diuretics: may enhance renal clearance changes; monitor renal function.
Nephrotoxic agents (e.g., aminoglycosides, NSAIDs): increase risk of renal injury; observe kidney parameters.
Iron chelators (e.g., deferoxamine): can alter gadolinium binding; watch for reduced efficacy.

Frequently Asked Questions

Multihance is a gadolinium‑based contrast agent used during magnetic resonance imaging to improve the visibility of internal structures. It is indicated for liver, central nervous system, cardiovascular and whole‑body MRI examinations, helping radiologists detect lesions, assess vascular anatomy and evaluate disease extent.

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons after intravenous injection. This creates a brighter signal on T1‑weighted MRI images, enhancing the contrast between blood vessels, tissues and pathological lesions, which facilitates more accurate diagnosis.

The dose of Multihance is determined by the prescribing physician based on the patient’s body weight, the specific MRI protocol and the anatomical region being examined. Typical dosing follows the product label, and the exact volume to be administered is set by the radiologist or ordering clinician.

Multihance is classified as Pregnancy Category C, meaning it should only be used when the potential diagnostic benefit justifies any possible risk to the fetus. Limited data are available for breastfeeding; therefore, the decision to continue nursing should be made in consultation with the treating physician.

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and assists with import documentation.

Multihance (gadobenate dimeglumine) is a linear gadolinium chelate that provides high relaxivity, offering strong vascular and tissue enhancement. Compared with macrocyclic agents such as gadobutrol, Multihance may deliver slightly higher signal intensity in certain liver and cardiac studies, but macrocyclic agents are generally considered to have a lower risk of nephrogenic systemic fibrosis in patients with severe renal impairment.

Multihance should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vial should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations for injectable pharmaceuticals.

Multihance is administered as an intravenous injection, typically as a rapid bolus or a power‑injector delivery, depending on the imaging protocol. The exact injection rate and volume are defined by the radiology department and the prescribing physician to achieve optimal contrast enhancement for the targeted MRI study.

The most serious risks include nephrogenic systemic fibrosis in patients with severe renal dysfunction and severe allergic reactions such as anaphylaxis. Cardiovascular collapse and rare severe skin reactions (e.g., Stevens‑Johnson syndrome) have also been reported. Prompt recognition and management of these events are essential.

Multihance should be avoided in patients with known severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis, and in individuals with a documented hypersensitivity to gadobenate dimeglumine or any component of the formulation. Caution is also advised for pregnant women and those with a history of severe allergic reactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.